Clinical context
Visual acuity alone is insufficient when judging corneal disease or surgery. Topography and tomography, surface regularity, biomechanics, endothelial cell density, quality of vision and stability all matter. After refractive procedures, epithelial healing, dry eye, haze, ectasia and the need for enhancement should be assessed separately.
What was studied
This retrospective nonrandomized single-surgeon study compared early results of Wavelight Plus ray-tracing LASIK and SMILE Pro, using wavefront-optimized LASIK as an internal benchmark. It analyzed 160 eyes of 93 patients: 50 WLP, 55 SMILE Pro and 55 WFO. Outcomes at one and three months included uncorrected and corrected distance vision, spherical equivalent, residual cylinder, safety and efficacy indices, and vector analysis of astigmatic correction.
How the evidence was produced
A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.
How to interpret the result
In this series, WLP produced faster and more precise early uncorrected vision, particularly through cylinder control. Procedure choice was not randomized, and the center had a mature WFO nomogram while WLP and SMILE Pro represented initial experience. Differences therefore cannot be assigned automatically to the platform. Patient selection still depends on topography, corneal thickness and biomechanics, myopia, dry eye, ectasia risk and preference for a flap-based or flap-free procedure.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The study may refine technique selection and informed discussion, but its conclusions depend on baseline corneal shape, stromal thickness, equipment, nomogram and surgeon experience. Applicability requires comparison of these factors and attention to variability, uncommon complications and follow-up duration rather than mean values alone.
Limitations
The study was retrospective, single-center and nonrandomized, with one surgeon. Some patients contributed both eyes, and three-month data were available for 40 WLP and 46 SMILE Pro eyes, creating attrition risk. Follow-up was too short to assess regression, ectasia, persistent dry eye or later enhancement. The full paper should be checked for procedure-selection criteria, group matching, treatment parameters, paired-eye statistics, adverse events, funding and completeness of follow-up.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.